Tarceva Pancreatic Cancer Indication Turned Down In The EU
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.
You may also be interested in...
EMEA’s CHMP Reverses Stance On Roche’s Tarceva
CHMP also recommends marketing authorization for J&J’s Prezista and Orphan Europe SARL’s Cystadane.
EMEA’s CHMP Reverses Stance On Roche’s Tarceva
CHMP also recommends marketing authorization for J&J’s Prezista and Orphan Europe SARL’s Cystadane.
Roche Appeals Negative EMEA Decision For Tarceva Pancreatic Cancer Indication
EMEA has 60 days to review Tarceva on appeal; the oncologic is approved for treatment of advanced pancreatic cancer in the U.S.